Trials / Recruiting
RecruitingNCT06690957
Somatostatin Receptor PET/CT in SSTR-Related Disease Patients
- Status
- Recruiting
- Phase
- —
- Study type
- Observational
- Enrollment
- 500 (estimated)
- Sponsor
- Tianjin Medical University · Academic / Other
- Sex
- All
- Age
- 18 Years – 80 Years
- Healthy volunteers
- Accepted
Summary
To evaluate the potential usefulness of 68Ga/18F-TATE/JR11/LM3 positron emission tomography/computed tomography (PET/CT) for the diagnosis of primary and metastatic lesions in various SSTR-related disease patients.
Detailed description
Subjects with various SSTR-related disease patients underwent 68Ga/18F-TATE/JR11/ LM3 PET/CT either for an initial assessment or for recurrence detection. Lesions uptake was quantified by the maximum standard uptake value (SUVmax). The sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV) and accuracy of 68Ga/18F-TATE/JR11/LM3 PET/CT were calculated.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DIAGNOSTIC_TEST | 68Ga/18F-TATE/JR11/LM3 | Each subject receive a single intravenous injection of 68Ga/18F-TATE/JR11/LM3, and undergo PET/CT imaging within the specificed time. |
Timeline
- Start date
- 2019-02-01
- Primary completion
- 2027-10-01
- Completion
- 2027-10-01
- First posted
- 2024-11-15
- Last updated
- 2025-02-11
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT06690957. Inclusion in this directory is not an endorsement.